New drug combo shows promise for elderly leukemia patients

This study tested a two-drug combination (azacitidine and venetoclax) as an initial treatment for adults aged 60 and older with acute myeloid leukemia (AML) who had not received prior therapy. Participants first received both drugs together, and those who responded continued on venetoclax alone to maintain remission. The goal was to see how long the remission lasted and how many patients achieved a complete response. The study enrolled 42 participants and has been completed.